Effects of human apolipoprotein E isoforms on the amyloid β-protein concentration and lipid composition in brain low-density membrane domains

Journal of Neurochemistry

Volumn 101, Issue 4, 2007, Pages 949-958

  Morishima Kawashima, Maho ^a   Han, Xianlin ^b   Tanimura, Yu ^a   Hamanaka, Hiroki ^c,d   Kobayashi, Mariko ^d   Sakurai, Takashi ^c   Yokoyama, Minesuke ^d   Wada, Koji ^c   Nukina, Nobuyuki ^c   Fujita, Shinobu C ^d   Ihara, Yasuo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^d MITSUBISHI KAGAKU INSTITUTE OF LIFE SCIENCES   (Japan)

Author keywords

Alzheimer's disease; Amyloid protein; Apolipoprotein E; Knock in mouse; Lipids; Low density membrane domains

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E;

ANIMAL TISSUE; ARTICLE; BRAIN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; LIPID COMPOSITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

AGE FACTORS; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; BRAIN CHEMISTRY; CEREBELLUM; HUMANS; LIPIDS; MALE; MEMBRANES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PROTEIN ISOFORMS; STATISTICS, NONPARAMETRIC;

MUS; MUS MUSCULUS;

EID: 34247639082     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04400.x     Document Type: Article

References (61)

1. Avdulov N. A., Chochina S. V., Igbavboa U., Warden C. S., Vassiliev A. V. Wood W. G. (1997) Lipid binding to amyloid β-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J. Neurochem. 69, 1746 1752.
2. Bales K. R., Verina T., Dodel R. C. et al. (1997) Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat. Genet. 17, 263 264.
3. Carter D. B., Dunn E., McKinley D. D., Stratman N. C., Boyle T. P., Kuiper S. L., Oostveen J. A., Weaver R. J., Boller J. A. Gurney M. E. (2001) Human apolipoprotein E4 accelerates β-amyloid deposition in APPsw transgenic mouse brain. Ann. Neurol. 50, 468 475.
4. Choo-Smith L. P. Surewicz W. K. (1997) The interaction between Alzheimer amyloid β (1-40) peptide and ganglioside GM1-containing membranes. FEBS Lett. 402, 95 98.
5. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Small G. W., Roses A. D., Haines J. L. Pericak-Vance M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921 923.
6. Enya M., Morishima-Kawashima M., Yoshimura M. et al. (1999) Appearance of sodium dodecyl sulfate-stable amyloid β-protein (Aβ) dimer in the cortex during aging. Am. J. Pathol. 154, 271 279.
7. Fagan A. M., Watson M., Parsadanian M., Bales K. R., Paul S. M. Holtzman D. M. (2002) Human and murine ApoE markedly alters Aβ metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9, 305 318.
8. Fassbender K., Simons M., Bergmann C. et al. (2001) Simvastatin strongly reduces concentrations of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 5856 5861.
9. Frears E. R., Stephens D. J., Walters C. E., Davies H. Austen B. M. (1999) The role of cholesterol in the biosynthesis of β-amyloid. Neuroreport 10, 1699 1705.
10. Fryer J. D., Simmons K., Parsadanian M., Bales K. R., Paul S. M., Sullivan P. M. Holtzman D. M. (2005) Human apolipoprotein E4 alters the amyloid-β 40:42 proportion and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 25, 2803 2810.
11. Funato H., Yoshimura M., Kusui K., Tamaoka A., Ishikawa K., Ohkoshi N., Namekata K., Okeda R. Ihara Y. (1998) Quantitation of amyloid β-protein (Aβ) in the cortex during aging and in Alzheimer's disease. Am. J. Pathol. 152, 1633 1640.
12. Gearing M., Mori H. Mirra S. S. (1996) Aβ-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann. Neurol. 39, 395 399.
13. Hamanaka H., Katoh-Fukui Y., Suzuki K. et al. (2000) Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. Hum. Mol. Genet. 9, 353 361.
14. Han X. (2004) The role of apolipoprotein E in lipid metabolism in the central nervous system. Cell. Mol. Life Sci. 61, 1896 1906.
15. Han X. Gross R. W. (2005a) Shotgun lipidomics: Electrospray ionization mass spectroscopic analysis and quantitation of the cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev. 24, 367 412.
16. Han X. Gross R. W. (2005b) Shotgun lipidomics: multi-dimensional mass spectrometric analysis of cellular lipidomes. Expert Rev. Proteomics 2, 253 264.
17. Han X., Cheng H., Fryer J. D., Fagan A. M. Holtzman D. M. (2003) Novel role for apolipoprotein E in the central nervous system. Modulation of sulfatide content. J. Biol. Chem. 278, 8043 8051.
18. Hayashi H., Igbavboa U., Hamanaka H., Kobayashi M., Fujita S. C., Wood W. G. Yanagisawa K. (2002) Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. Neuroreport 13, 383 386.
19. Holtzman D. M. Fagan A. M. (1998) Potential role of apoE in structural plasticity in the nervous system; implications for disorders of the central nervous system. Trends Cardiovasc. Med. 8, 250 255.
20. Holtzman D. M., Bales K. R., Wu S., Bhat P., Parsadanian M., Fagan A. M., Chang L. K., Sun Y. Paul S. M. (1999) Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103, R15 R21.
21. Holtzman D. M., Bales K. R., Tenkova T. et al. (2000) Apolipoprotein E isoform-specific amyloid deposition and neuritic degeneproportionn in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 97, 2892 2897.
22. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F. Cole G. (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99 102.
23. Igbavboa U., Eckert G. P., Malo T. M. et al. (2005) Murine synaptosomal lipid raft protein and lipid composition are altered by expression of human apoE 3 and 4 and by increasing age. J. Neurol. Sci. 229-230, 225 232.
24. Irizarry M. C., Rebeck G. W., Cheung B., Bales K., Paul S. M., Holzman D. Hyman B. T. (2000) Modulation of Aβ deposition in APP transgenic mice by an apolipoprotein E null background. Ann. N Y Acad. Sci. 920, 171 178.
25. Jick H., Zornberg G. L., Jick S. S., Seshadri S. Drachman D. A. (2000) Statins and the risk of dementia. Lancet 356, 1627 1631.
26. Kakio A., Nishimoto S. I., Yanagisawa K., Kozutsumi Y. Matsuzaki K. (2001) Cholesterol-dependent for mation of GM1 ganglioside-bound amyloid β-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem. 276, 24985 24990.
27. Kawarabayashi T., Shoji M., Younkin L. H., Wen-Lang L., Dickson D. W., Murakami T., Matsubara E., Abe K., Ashe K. H. Younkin S. G. (2004) Dimeric amyloid β protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 24, 3801 3809.
28. Kokubo H., Kayed R., Glabe C. G., Saido T. C., Iwata N., Helms J. B. Yamaguchi H. (2005a) Oligomeric proteins ultrastructurally localize to cell processes, especially to axon terminals with higher density, but not to lipid rafts in Tg2576 mouse brain. Brain Res. 1045, 224 228.
29. Kokubo H., Saido T. C., Iwata N., Helms J. B., Shinohara R. Yamaguchi H. (2005b) Part of membrane-bound Aβ exists in rafts within senile plaques in Tg2576 mouse brain. Neurobiol. Aging 26, 409 418.
30. LaDu M. J., Reardon C., Van Eldik L., Fagan A. M., Bu G., Holtzman D. Getz G. S. (2000) Lipoproteins in the central nervous system. Ann. N Y Acad. Sci. 903, 167 175.
31. Lee S. J., Liyanage U., Bickel P. E., Xia W., Lansbury P. T. Jr. Kosik K. S. (1998) A detergent-insoluble membrane compartment contains Aβin vivo. Nat. Med. 4, 730 734.
32. Lehman E. J., Kulnane L. S., Gao Y., Petriello M. C., Pimpis K. M., Younkin L., Dolios G., Wang R., Younkin S. G. Lamb B. T. (2003) Genetic background regulates β-amyloid precursor protein processing and β-amyloid deposition in the mouse. Hum. Mol. Genet. 12, 2949 2956.
33. Lesuisse C., Xu G., Anderson J. et al. (2001) Hyper-expression of human apolipoprotein E4 in astroglia and neurons does not enhance amyloid deposition in transgenic mice. Hum. Mol. Genet. 10, 2525 2537.
34. Li G., Higdon R., Kukull W. A. et al. (2004) Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63, 1624 1628.
35. Mann K. M., Thorngate F. E., Katoh-Fukui Y., Hamanaka H., Williams D. L., Fujita S. Lamb B. T. (2004) Independent effects of APOE on cholesterol metabolism and brain Aβ concentrations in an Alzheimer disease mouse model. Hum. Mol. Genet. 13, 1959 1968.
36. Mori T., Kobayashi M., Town T., Fujita S. C. Asano T. (2003) Increased vulnerability to focal ischemic brain injury in human apolipoprotein E4 knock-in mice. J. Neuropathol. Exp. Neurol. 62, 280 291.
37. Morishima-Kawashima M. Ihara Y. (1998) The presence of amyloid β-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry 37, 15247 15253.
38. Morishima-Kawashima M., Oshima N., Ogata H., Yamaguchi H., Yoshimura M., Sugihara S. lhara Y. (2000) Effect of apolipoprotein E allele ε4 on the initial phase of amyloid β-protein accumulation in the human brain. Am. J. Pathol. 157, 2093 2099.
39. Oshima N., Morishima-Kawashima M., Yamaguchi H., Yoshimura M., Sugihara S., Khan K., Games D., Schenk D. Ihara Y. (2001) Accumulation of amyloid β-protein in the low-density membrane domain accurately reflects the extent of β-amyloid deposition in the brain. Am. J. Pathol. 158, 2209 2218.
40. Qi Y., Morishima-Kawashima M., Sato T., Mitsumori R. Ihara Y. (2003) Distinct mechanisms by mutant presenilin 1 and 2 leading to increased intracellular levels of amyloid β-protein 42 in Chinese hamster ovary cells. Biochemistry 42, 1042 1052.
41. Ravona-Springer R., Davidson M. Noy S. (2003) The role of cardiovascular risk factors in Alzheimer's disease. CNS Spectr. 8, 824 833.
42. Rea T. D., Breitner J. C., Psaty B. M. et al. (2005) Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch. Neurol. 62, 1047 1051.
43. Refolo L. M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G. S., Sambamurti K., Duff K. Pappolla M. A. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321 331.
44. Sawamura N., Morishima-Kawashima M., Waki H. et al. (2000) Mutant presenilin 2 transgenic mice. A large increase in the concentrations of Aβ42 is presumably associated with the low density membrane domain that contains decreased concentrations of blycerophospholipids and sphingomyelin. J. Biol. Chem. 275, 27901 27908.
45. Schmechel D. E., Saunders A. M., Strittmatter W. J., Crain B. J., Hulette C. M., Joo S. H., Pericak-Vance M. A., Goldgaber D. Roses A. D. (1993) Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease. Proc. Natl Acad. Sci. USA 90, 9649 9653.
46. Simons K. Ikonen E. (1997) Functional rafts in cell membranes. Nature 387, 569 572.
47. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C. G. Simons K. (1998) Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95, 6460 6464.
48. Skoog I., Nilsson L., Palmertz B., Andreasson L. A. Svanborg A. (1993) A population-based study of dementia in 85-year-olds. N. Engl. J. Med. 328, 153 158.
49. Sparks D. L., Scheff S. W., Hunsaker J. C. III., Liu H., Landers T. Gross D. R. (1994) Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol 126, 88 94.
50. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S. Roses A. D. (1993) Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 1977 1981.
51. Wahrle S., Das P., Nyborg A. C., McLendon C., Shoji M., Kawarabayashi T., Younkin L. H., Younkin S. G. Golde T. E. (2002) Cholesterol-dependent γ-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9, 11 23.
52. Walker L. C., Pahnke J., Madauss M., Vogelgesang S., Pahnke A., Herbst E. W., Stausske D., Walther R., Kessler C. Warzok R. W. (2000) Apolipoprotein E4 promotes the early deposition of Aβ42 and then Aβ40 in the elderly. Acta Neuropathol. (Berl.) 100, 36 42.
53. Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S., Rowan M. J. Selkoe D. J. (2002) Naturally secreted oligomers of amyloid β potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535 539.
54. Weisgraber K. H. (1994) Apolipoprotein E: structure-function relationships. Adv. Protein Chem. 45, 249 302.
55. Weisgraber K. H. Mahley R. W. (1996) Human apolipoprotein E: the Alzheimer's disease connection. FASEB J. 10, 1485 1494.
56. Wisniewski T., Castano E. M., Golabek A., Vogel T. Frangione B. (1994) Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145, 1030 1035.
57. Wolozin B., Kellman W., Ruosseau P., Celesia G. G. Siegel G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439 1443.
58. Wong G. T. (2002) Speed congenics: applications for transgenic and knock-out mouse strains. Neuropeptides 36, 230 236.
59. Wood W. G., Schroeder F., Igbavboa U., Avdulov N. A. Chochina S. V. (2002) Brain membrane cholesterol domains, aging and amyloid β-peptides. Neurobiol. Aging 23, 685 694.
60. Yamaguchi H., Maat-Schieman M. L., van Duinen S. G., Prins F. A., Neeskens P., Natte R. Roos R. A. (2000) Amyloid β protein (Aβ) starts to deposit as plasma membrane-bound form in diffuse plaques of brains from hereditary cerebral hemorrhage with amyloidosis-Dutch type, Alzheimer disease and nondemented aged subjects. J. Neuropathol. Exp. Neurol. 59, 723 732.
61. Yao J., Petanceska S. S., Montine T. J. et al. (2004) Aging, gender and APOE isotype modulate metabolism of Alzheimer's Aβ peptides and F-isoprostanes in the absence of detectable amyloid deposits. J. Neurochem. 90, 1011 1018.